GlassScriptPhysician profile
Alex C Spyropoulos
NPI 1073622874
$632,907.08
in general payments reported to CMS, 2019-2025
22 companies · $123K in 2025
The $123K reported for 2025 was more than what 99% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $154K · 2020: $84K · 2021: $135K · 2022: $70K · 2023: $33K · 2024: $34K · 2025: $123K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $164K · Travel and Lodging: $23K · Food and Beverage: $2,887.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $164,110.50 |
| Travel and Lodging | $23,184.35 |
| Food and Beverage | $2,886.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Research & Development, LLC | $154,280.09 | 2019-2023 | Xarelto |
| Janssen Scientific Affairs, LLC | $136,310.27 | 2019-2024 | Xarelto |
| Janssen Pharmaceuticals, INC | $99,136.49 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $82,244.77 | 2022-2025 | Andexxa |
| Daiichi Sankyo INC. | $35,393.65 | 2024-2025 | Savaysa |
| Grifols Shared Services North America, INC. | $21,030.49 | 2022-2025 | Thrombate III |
| Sanofi-Aventis U.S. LLC | $14,891.44 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $13,918.20 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $12,720.00 | 2020-2022 | |
| Janssen Global Services, LLC | $12,074.51 | 2020 | |
| Novartis Pharmaceuticals Corporation | $10,631.89 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $10,060.36 | 2019-2021 | |
| Btg International INC. | $9,903.53 | 2025 | |
| Diagnostica Stago, INC | $4,000.00 | 2020 | |
| Roche Diagnostics International LTD | $3,990.00 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $3,055.70 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $2,621.50 | 2022 | |
| Siemens Medical Solutions USA, INC. | $2,250.00 | 2021 | |
| Alexion Pharmaceuticals, INC. | $1,879.52 | 2021-2022 | |
| Portola Pharmaceuticals, LLC | $1,864.67 | 2019 | |
| Arbor Pharmaceuticals, INC. | $650.00 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alex Spyropoulos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.